HPLC/UPLC instruments for biopharma

01Overview and value chain#

Markers EC: US FDA 21 CFR Part 11 + USP <621>/<1058> for chromatographic system validation | OECD: Bio-pharmaceuticals | Regulator: FDA (USA), EMA (EU), NMPA (China)

HPLC and UPLC instruments separate the components of a liquid sample by pumping it under high pressure through a column packed with a stationary phase, resolving proteins, peptides, small molecules and impurities into discrete, individually detectable peaks before UV, fluorescence, or mass-spectrometry detection. Ultra-high-performance liquid chromatography (UPLC/UHPLC) pushes the same separation principle to sub-2-micron particle columns and pressures above 15,000 psi, delivering sharper peaks, faster run times and higher resolution than conventional HPLC’s 3-5-micron media. The instrument is the single most common analytical workhorse in a biopharma QC lab: a purity assay, a charge-variant analysis, a host-cell-protein clearance check and a formulation stability study all run on the same basic pump-column-detector architecture, differing mainly in column chemistry and detection mode. Speed has become a competitive axis in the current generation — vendors report run-time reductions of 2-3x for specific bioseparation applications such as GLP-1 peptide characterization and LNP component analysis, driven by new reversed-phase column chemistries paired with faster-scanning detectors.

The key directions of HPLC/UPLC instrumentation are:

1. Ultra-high-performance liquid chromatography (UPLC/UHPLC): sub-2-micron column particles and pressures above 15,000 psi deliver sharper resolution and faster run times than conventional HPLC, now the default for high-throughput biopharma QC.
2. Reversed-phase bioseparation chromatography (RP Bioseparation): column chemistries purpose-built for peptide, protein and LNP-component separation, delivering faster run times for applications such as GLP-1 characterization and mRNA-LNP QC.
3. Size-exclusion and ion-exchange chromatography (SEC/IEX): separation by molecular size or charge rather than hydrophobicity, used for aggregate quantitation and charge-variant analysis of therapeutic proteins.
4. LC-MS hyphenation (LC-MS Coupling): liquid chromatography feeding directly into a mass spectrometer, turning a chromatographic separation into a combined identity and purity measurement.

Sectoral value chain#

[Liquid sample] ──> [High-pressure pump] ──> [Column separation] ──> [Detection: UV/fluorescence/MS]
                                                                  │
                                                          (peak identification)
                                                                  │
                                                                  ▼
[Purity/identity/quantitation report] <─── [Software: peak integration, chromatogram comparison]

Value chain levels#

Cross-cutting technologies of the sector:

• Sub-2-micron core-shell particles: superficially porous column media approach UPLC resolution at conventional HPLC pressures, extending high-resolution separation to instruments without full UHPLC pump capability.
• Multi-detector hyphenation: photodiode-array UV, fluorescence and mass-spectrometry detectors are increasingly run in parallel off a single chromatographic separation.
• Automated method-transfer software: vendor tools now translate a validated method between HPLC and UPLC platforms, adjusting flow rate and gradient to preserve selectivity across instrument generations.

02US#

The US hosts the category’s largest instrument makers and the deepest biopharma purity-testing and release-assay demand, spanning discovery characterization through GxP QC.

bioseparation column chemistry, UHPLC speed leadership, mass-spec-coupled release testing#

• Waters Corporation: the ACQUITY Premier UPLC platform and new reversed-phase bioseparation columns deliver up to 3x faster GLP-1 peptide characterization and 2x faster LNP-component analysis, alongside LC-MS platform methodologies supporting upstream bioprocess optimization.
• Agilent Technologies: the 1290 Infinity II binary UHPLC system extends the established 1290 Infinity line with higher throughput and resolution for biopharma and small-molecule analysis.
• Thermo Fisher Scientific: the Vanquish Horizon UHPLC system is positioned for high-throughput liquid chromatography, emphasizing maximized data output and minimized downtime for productivity-focused QC labs.

03CN#

No China-headquartered HPLC/UPLC instrument maker cleared this screening round with confirmed, on-domain evidence; demand is driven by China’s expanding biopharma purity-testing and QC-release base, currently served largely through the same global vendors’ regional distribution and applications-support networks.

import-dependent instrumentation, domestic biopharma QC demand, distributor-served market#

• Global vendor distribution: Waters, Agilent, Thermo Fisher and Shimadzu each maintain China sales and applications-support organizations serving domestic biopharma and QC laboratories.
• Domestic biopharma QC build-out: China’s growing biologics manufacturing and purity-testing base is the main demand driver for HPLC/UPLC instrumentation, without a confirmed domestic instrument originator identified in this screen.
• Screening note: two candidate China-headquartered instrument makers were probed and neither returned confirming, on-domain evidence this round — not asserted as absent, only as unconfirmed.

04EU#

Germany contributes both a global instrument giant’s manufacturing base and an independent owner-managed specialist, giving Europe a distinct competitive shape from the US’s vendor concentration.

owner-managed instrument engineering, FPLC/UHPLC bio-application focus, independent European specialist#

• Knauer (Germany): based in Berlin and family-owned since 1962, Knauer’s AZURA Bio Lab FPLC and AZURA HTQC UHPLC systems are positioned specifically for biopharma and life-science separation applications, an independent alternative to the US instrument majors.

05Leading companies and research institutes#

06Tech stack and innovations#

The stack layers high-pressure fluidics, column chemistry and detection on a common chromatography-data-software backbone, with the UPLC/HPLC choice driven by the resolution and throughput the application requires.

1. Sub-2-micron UPLC column technology:
   • Smaller stationary-phase particles increase the theoretical plate count per unit column length, sharpening peaks and improving resolution at the cost of higher backpressure.
   • Pumps rated above 15,000 psi and low-dispersion flow paths are required to run these columns without band-broadening that would erase the resolution gain.
2. Reversed-phase bioseparation column chemistry:
   • Column surface chemistries engineered specifically for peptide and protein hydrophobicity profiles improve peak shape and resolution for biotherapeutic molecules versus general-purpose reversed-phase media.
   • Purpose-built chemistries for GLP-1 peptides and LNP lipid components deliver measured 2-3x run-time reductions over prior-generation columns.
3. LC-MS hyphenation:
   • The chromatography outlet feeds directly into a mass spectrometer’s ionization source, so each separated peak carries both a retention time and a mass spectrum.
   • Turns a purity separation into a combined identity-and-purity measurement in one run, supporting upstream bioprocess optimization and impurity characterization.

07Value chains and production pipelines#

Industrial pipeline of a biopharma purity/release chromatography run (USP <621>/<1058> / 21 CFR Part 11)#

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Sample preparation      │ ───> │ 2. Injection & pumping      │
└───────────────────────────┘      └───────────────────────────┘
                                                 │
                                                 ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Detection                │ <─── │ 3. Column separation        │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Peak integration        │ ───> │ 6. Purity/release report   │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: Sample preparation

The sample is filtered to remove particulates and diluted or derivatized as needed to match the column’s loading capacity and the detector’s linear response range.

Stage 2: Injection and pumping

An autosampler injects a precise volume onto the column while a binary or quaternary pump delivers a controlled solvent gradient at pressures appropriate to the column’s particle size.

Stage 3: Column separation

The sample partitions between the mobile phase and the column’s stationary phase, separating into discrete components that elute at characteristic retention times.

Stage 4: Detection

UV/Vis, fluorescence or mass-spectrometry detectors measure each eluting peak, generating the raw chromatographic signal.

Stage 5: Peak integration

Chromatography data software integrates peak areas, assigns identities by retention time or mass, and flags any new, missing or shifted peaks relative to a reference method.

Stage 6: Purity or release report

The integrated results are compared against a validated method specification under USP <621>/<1058>, with a 21 CFR Part 11-compliant audit trail generating the purity, identity or batch-release determination.